FI106857B - Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI106857B
FI106857B FI942289A FI942289A FI106857B FI 106857 B FI106857 B FI 106857B FI 942289 A FI942289 A FI 942289A FI 942289 A FI942289 A FI 942289A FI 106857 B FI106857 B FI 106857B
Authority
FI
Finland
Prior art keywords
het
compound
methyl
eller
hydrogen
Prior art date
Application number
FI942289A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942289A0 (fi
FI942289A (fi
Inventor
Lars-Inge Olsson
Karl Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Goeran Smedegaard
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI942289A0 publication Critical patent/FI942289A0/fi
Publication of FI942289A publication Critical patent/FI942289A/fi
Application granted granted Critical
Publication of FI106857B publication Critical patent/FI106857B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • C07D261/16Benzene-sulfonamido isoxazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
FI942289A 1991-11-18 1994-05-17 Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi FI106857B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9103397 1991-11-18
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
SE9200758 1992-11-04
PCT/SE1992/000758 WO1993010094A1 (fr) 1991-11-18 1992-11-04 Nouveaux acides salicyliques substitues

Publications (3)

Publication Number Publication Date
FI942289A0 FI942289A0 (fi) 1994-05-17
FI942289A FI942289A (fi) 1994-05-17
FI106857B true FI106857B (fi) 2001-04-30

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942289A FI106857B (fi) 1991-11-18 1994-05-17 Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi

Country Status (29)

Country Link
US (3) US5302718A (fr)
EP (1) EP0613468B1 (fr)
JP (1) JP3259915B2 (fr)
KR (1) KR100253748B1 (fr)
AT (1) ATE194597T1 (fr)
AU (1) AU668528B2 (fr)
CA (1) CA2123697C (fr)
DE (1) DE69231252T2 (fr)
DK (1) DK0613468T3 (fr)
EE (1) EE03026B1 (fr)
ES (1) ES2149780T3 (fr)
FI (1) FI106857B (fr)
GR (1) GR3034585T3 (fr)
HU (2) HU221476B (fr)
IL (1) IL103665A (fr)
LT (1) LT3182B (fr)
LV (1) LV10246B (fr)
MX (1) MX9206647A (fr)
MY (1) MY130169A (fr)
NO (1) NO300805B1 (fr)
NZ (1) NZ244998A (fr)
PT (1) PT101068B (fr)
RU (1) RU2124501C1 (fr)
SE (1) SE9103397D0 (fr)
SK (1) SK282080B6 (fr)
TW (1) TW304944B (fr)
UA (1) UA42869C2 (fr)
WO (1) WO1993010094A1 (fr)
ZA (1) ZA928864B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
WO1997010813A1 (fr) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Antagonistes de ppar gamma pour le traitement de l'obesite
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
NZ330464A (en) 1996-02-20 2000-04-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 4−フルオロサリチル酸類
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2003520758A (ja) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のrxrモジュレーターを用いた処置
KR20020004974A (ko) 1999-03-19 2002-01-16 스티븐 비. 데이비스 비페닐 이속사졸 술폰아미드의 제조방법
ES2216940T3 (es) 1999-09-04 2004-11-01 Astrazeneca Ab Derivados n-fenilicos de 2-hidroxi-2-metil-3,3,3-trifluoropropanamida sustituidos que elevan la actividad de piruvato deshidrogenasa.
DE60031699T2 (de) 1999-09-04 2007-08-30 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
WO2001017942A1 (fr) 1999-09-04 2001-03-15 Astrazeneca Ab Amides inhibiteurs pour la pyruvate deshydrogenase
CA2307278A1 (fr) * 2000-04-28 2001-10-28 University Of British Columbia Utilisation d'acides salicyliques substitues comportant un heterocycle azote pour l'inhibition de l'assimilation cellulaire de la cystine
ATE311189T1 (de) * 2000-04-28 2005-12-15 Univ British Columbia N-heterosubstituierten salicylaten zur behandlung von krebs
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US7732442B2 (en) 2003-09-05 2010-06-08 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonist and medical use thereof
EP1696915A1 (fr) * 2003-12-19 2006-09-06 Pfizer, Inc. Derives de benzenesulfonylamino-pyridin-2yl et composes apparentes en tant qu'inhibiteurs de la 11-beta-hydeoxysteroide deshydrogenase type 1 (11-beta-hsd-1) pour le traitement du diabete et de l'obesite
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー P2x7受容体のベンズアミド阻害剤を利用する併用療法
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
MX2008010668A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
JP5304785B2 (ja) * 2008-06-23 2013-10-02 アステラス製薬株式会社 スルホンアミド化合物又はその塩
CN103547152A (zh) * 2011-02-23 2014-01-29 西奈山伊坎医学院 溴结构域蛋白的抑制剂作为基因表达的调节剂
RS60353B1 (sr) 2015-05-20 2020-07-31 Amgen Inc Agonisti triazola apj receptora
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
WO2017192485A1 (fr) 2016-05-03 2017-11-09 Amgen Inc. Composés triazole hétérocycliques utilisés en tant qu'agonistes du récepteur apj
EP3541805B1 (fr) 2016-11-16 2020-10-14 Amgen Inc. Triazoles substitués par hétéroaryle utilisés en tant qu'agonistes du récepteur apj
EP3541803B1 (fr) 2016-11-16 2020-12-23 Amgen Inc. Composés de triazole pyridyle en tant qu'agonistes du récepteur apj
WO2018097944A1 (fr) 2016-11-16 2018-05-31 Amgen Inc. Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj
WO2018093576A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
EP3704122B1 (fr) 2017-11-03 2021-09-01 Amgen Inc. Agonistes de triazole fusionnés du récepteur apj
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
LV10246B (en) 1995-04-20
US5556855A (en) 1996-09-17
GR3034585T3 (en) 2001-01-31
SE9103397D0 (sv) 1991-11-18
HUT69723A (en) 1995-09-28
DE69231252D1 (de) 2000-08-17
FI942289A0 (fi) 1994-05-17
JPH07501330A (ja) 1995-02-09
US5403930A (en) 1995-04-04
CA2123697C (fr) 2003-12-09
ES2149780T3 (es) 2000-11-16
LT3182B (en) 1995-03-27
EE03026B1 (et) 1997-08-15
EP0613468B1 (fr) 2000-07-12
NO941799D0 (no) 1994-05-13
RU2124501C1 (ru) 1999-01-10
IL103665A0 (en) 1993-04-04
ATE194597T1 (de) 2000-07-15
DK0613468T3 (da) 2000-10-23
NO941799L (fr) 1994-06-22
TW304944B (fr) 1997-05-11
LTIP229A (en) 1994-09-25
EP0613468A1 (fr) 1994-09-07
SK54794A3 (en) 1995-02-08
JP3259915B2 (ja) 2002-02-25
KR100253748B1 (ko) 2000-05-01
AU2958992A (en) 1993-06-15
AU668528B2 (en) 1996-05-09
SK282080B6 (sk) 2001-10-08
UA42869C2 (uk) 2001-11-15
ZA928864B (en) 1993-05-13
NO300805B1 (no) 1997-07-28
CA2123697A1 (fr) 1993-05-27
IL103665A (en) 1997-08-14
HU9401391D0 (en) 1994-08-29
MX9206647A (es) 1993-05-01
DE69231252T2 (de) 2001-03-01
NZ244998A (en) 1995-09-26
FI942289A (fi) 1994-05-17
HU211163A9 (en) 1995-10-30
PT101068A (pt) 1994-02-28
HU221476B (en) 2002-10-28
PT101068B (pt) 1999-08-31
MY130169A (en) 2007-06-29
WO1993010094A1 (fr) 1993-05-27
US5302718A (en) 1994-04-12
LV10246A (lv) 1994-10-20

Similar Documents

Publication Publication Date Title
FI106857B (fi) Menetelmä uusien farmakologisesti aktiivisten salisyylihappojohdannaisten valmistamiseksi
FR2581993A1 (fr) Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
JPH09502448A (ja) 心臓血管系に活性な2−アミノ−1,2,3,4−テトラヒドロナフタレン誘導体
CA1277669C (fr) Derive d'un ester quanidinobenzoique
FR2758329A1 (fr) Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
US6727266B2 (en) Substituted tryptophan derivatives
JPH07267954A (ja) 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1ノナン−化合物、その製法及び抗不整脈剤
EP0377977A1 (fr) Dérivés de la glycine et procédé pour leur préparation
US5356922A (en) Imidazole compounds, processes for their preparation, pharmaceuticals based on these compounds and some intermediates
EP0718307A2 (fr) Dérivés de 1-oxo-2-(phénylsulfonyl-amino)pentylpipéridine, leur préparation et leur application en thérapeutique
WO2008111794A1 (fr) Dérivés de 4-méthylimidazol-5-ylcarbonylguanidine, leurs sels pharmaceutiquement acceptables, procédés de préparation et compositions pharmaceutiques pour la prévention et le traitement des maladies cardiaques ischémiques contenant ceux-ci comme ingrédient actif
US4628057A (en) Tetrahydro-β-carboline derivatives and treatment of liver diseases
JP2535528B2 (ja) 〔2−(1,3−ベンゾジオキソ−ル−5−イル)エチル〕チオ誘導体
EP0150463A1 (fr) Dihydro-4,5 vinyl-6 2H-pyridazinones-3 substituées et vinyl-6 2H-pyridazinones-3 substituées et procédé pour leur préparation
CZ287285B6 (cs) Nové substituované salicylové kyseliny
JPH05279336A (ja) フェノキシ酢酸誘導体
JPH051063A (ja) ピラゾロピリジン誘導体及びその製造法
JPS61282366A (ja) イミダゾ−ル誘導体
JPH04247077A (ja) トロポロン誘導体およびそれを有効成分とする虚血性疾患の予防・治療剤
JPH05221983A (ja) 新規なジヒドロピリジン誘導体
JPS62181244A (ja) 4〔4−(4−クロロフエニル)ブトキシ〕フエニルメチルアミン誘導体とその酸付加塩及びその製造方法
JPS5811437B2 (ja) 1−スルフイニル−1−チオ−2−(3−クロロ−4−アリルオキシフエニル)エチレン

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: PHARMACIA AB

MA Patent expired